Skip to content
Medical Health Aged Care

Structure of a key “trigger” of the immune response solved

Monash University 2 mins read

An international collaboration, involving researchers from Monash University and the University of Oxford, has led to a breakthrough in our understanding of how immune responses are started. The study has just been published in Nature.

The human immune system comprises multiple important white blood cells (i.e., lymphocytes) including B cells and T cells that fight off infections and cancers. Basic discoveries leading to an understanding of how lymphocytes function have led to the development of immunotherapies and vaccines. 

There are two types of T cells in humans, called αβ T-cells and γδ T cells, each of which expresses on their surfaces either an αβ T cell receptor (TCR) or a γδ TCR, respectively. In 1957, Frank Macfarlane Burnet, a famous Australian immunologist, predicted the existence of these receptors and speculated that they would “trigger” clonal lymphocyte expansions, producing enough cells to fight off infections. We now recognize that TCRs have the pivotal role of recognising molecules derived from foreign pathogens or tumours. While less is known about γδ T cells than αβ T cells, they are emerging as key players in immune defence and are becoming increasingly important for immunotherapy.

The team, using a technique called cryogenic electron microscopy, determined the molecular structure of the TCR that is found on the surface of γδ T cells. This technically demanding project took over a decade from conception to completion and was made possible by the expertise within the Monash Ramaciotti Centre for Cryo-Electron Microscopy.

The new structure unexpectedly showed that the γδ TCR is remarkably flexible, in stark contrast to relatively rigid αβ TCRs. The work also showed that the γδ TCR is very likely the more primeval receptor and completes the initial structural analysis of Burnet’s “trigger” receptors, alongside a companion paper also published in Nature.

“This flexibility is key to the ability of the γδ TCR receptor to recognise a wide array of binding partners, which underscores the unique role it plays in the human immune system”, Dr Benjamin Gully, co-first author of the study stated.

According to Professor Simon Davis, from Oxford University and joint senior author of the study, γδ T-cells are becoming increasingly important therapeutically.

“The new structure helps constrain theories of how TCRs trigger lymphocytes, and should be helpful, especially, for re-engineering TCRs and optimising their use in the clinic” he said.

The authors would like to acknowledge support from the Australian Research Council Discovery Program which made this basic research project possible.

A diagram of different types of cell proteinDescription automatically generated with medium confidence

Figure. The image shows the unusual, flexible arrangement of the γδ TCR versus the αβ TCR. B-cell receptor is expressed by antibody-making B-cells.

 

 


Contact details:

For media enquiries please contact:

 

Monash University

Tania Ewing Media and Communications Contractor
E:
tania.ewing1@monash.edu

T: +61 (0) 408 378 422

 

For more Monash media stories, visit our news and events site 


For general media enquiries please contact:
Monash Media
E: media@monash.edu
T: +61 (0) 3 9903 4840

More from this category

  • Medical Health Aged Care
  • 12/09/2024
  • 09:45
Royal Australian College of GPs

RACGP welcomes government ban on genetic testing discrimination in life insurance

The Royal Australian College of GPs (RACGP) welcomes the Federal Government announcing it will legislate to ban the use of genetic test results in life insurance underwriting. In a submission in response to a Federal Treasury consultation paper, the RACGP said the medical benefits of genetic testing risked being lost if Australians avoid testing because it could lead to them being denied insurance. RACGP President Dr Nicole Higgins said: “The RACGP welcomes the Government announcing that it will legislate a full ban on the use of adverse genetic testing results by life insurers. “Genetic testing has great potential to improve…

  • Medical Health Aged Care
  • 12/09/2024
  • 08:11
Neuraptive Therapeutics, Inc.

Neuraptive Therapeutics Receives FDA Breakthrough Therapy Designation for NTX-001 and Provides Update on the Advancements of NTX-001 for the Treatment of Peripheral Nerve Injury Requiring Repair

– Breakthrough Therapy designation for NTX-001 granted by FDA – Preparation is underway for the Phase 3 program to begin in early 2025 CHESTERBROOK,…

  • Contains:
  • Medical Health Aged Care
  • 12/09/2024
  • 07:03
Monash University

Victorians Gain Access to Cutting-Edge Precision Cancer Therapies Thanks to Landmark $10M Donation

Cabrini Health, in partnership with Monash University, is set to transform cancer care for Victorians, thanks to a game-changing $10 million donation. This landmark funding will establish a cutting-edge genomic testing program at Cabrini providing personalised, precision treatment for up to 2,000 additional patients annually. The generous $10 million donation from the PMF Foundation was inspired by the personal experience of a patient under the care of Professor Gary Richardson OAM, Group Director of Cabrini Research and medical oncologist at Cabrini Hospital, who also holds a professorial appointment at Monash University. PMF Foundation Managing Director, Nicola Clyne, said: "The patient…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.